FDA opioid approvals relied on short trials, patient exclusions, study contends

None of the clinical trials for opioids the FDA approved to treat chronic pain from 1997 to 2018 lasted longer than three months, according to research published Sept. 29 in Annals of Internal Medicine.

Researchers discovered that only 21 of the 39 opioids approved by the FDA from 1997 to 2018 were supported by at least one pivotal trial. The median length of the trials conducted for opioids during this time was 84 days.

The study also found that of the 21 products backed by a pivotal trial, 17 (81 percent) excluded participants who could not tolerate the drugs, and most trials failed to examine risks associated with tolerance, addiction and drug diversion. Its conclusion states that "systematic collation of certain important safety outcomes was rare."

More articles on opioids:
Senators urge bankruptcy judge to block Purdue Pharma CEO's $3.5 million bonus
New York hits J&J with lawsuit over opioid marketing
Taxing drugmakers, distributors for opioid treatment programs upheld by US appeals court

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Featured Content

Featured Webinars

Featured Whitepapers